At the news
? MIXEDIMPACT 6/10 8-K filed Aug 6, 2026 at 07:11 ET
Tarsus Pharmaceuticals announced an oversubscribed $125.0 million PIPE financing concurrent with its pending acquisition of Alkeus Pharmaceuticals. The company is selling 2,098,519 shares at $56.00/share and 133,625 pre-funded warrants at $55.9999 each to a syndicate including existing Alkeus investors (TCGX, Bain Capital Life Sciences, Wellington Management) and new/existing Tarsus investors. Proceeds will fund clinical development and commercial activities. The PIPE provides near-term funding certainty for the Alkeus acquisition and pipeline, but the ~9% dilution at a price below the prior close is a modest negative for existing holders.
- Gross proceeds of approximately $125.0 million from a PIPE financing.
- Sale of 2,098,519 shares of common stock at $56.00 per share and 133,625 pre-funded warrants at $55.9999 each.
- PIPE includes participation from existing Alkeus investors (TCGX, Bain Capital Life Sciences, Wellington Management) and new/existing Tarsus investors (ADAR1 Capital Management, Sirenia Capital Management, RTW Investments, Vestal Point Capital).
- PIPE is concurrent with the pending acquisition of Alkeus Pharmaceuticals, Inc. via a Merger Agreement dated July 31, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access